Login to Your Account

Inspiration Files BLA, Prepares to Market Factor IX Therapy

By Catherine Shaffer
Staff Writer

Wednesday, April 18, 2012
Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., submitted a biologics license application (BLA) to the FDA for IB1001, a recombinant Factor IX therapy for hemophilia B. If approved, IB1001 would be the first new recombinant therapy for the disease in 15 years.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription